United States Urological Cancer Drugs Market Report 2017

February 2017 | 124 pages | ID: U5254C796A7EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Urological Cancer Drugs

Revenue, means the sales value of Urological Cancer Drugs

This report studies sales (consumption) of Urological Cancer Drugs in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• Novartis
• Pfizer
• Johnson & Johnson
• AstraZeneca
• Astellas
• Bristol-Myers Squibb
• Abbott Laboratories
• Celgene Corporation
• Dendreon Corporation
• Ferring Pharmaceuticals
• GlaxoSmithKline
• Indevus Pharmaceuticals Inc
• Ipsen
• Roche Healthcare
• Sanofi S.A.
• Tolmar Inc

Market Segment by States, covering

• California
• Texas
• New York
• Florida
• Illinois

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Xofigo (Radium Ra 223 Dichloride)
• Jevtana (Cabazitaxel)
• Inlyta (Axitinib)
• Votrient (Pazopanib Hydrochloride)
• Sutent (Sunitinib Malate)
• Zytiga (Abiraterone Acetate)
• Xtandi (Enzalutamide)
• Opdivo (Nivolumab)
• Provenge (Sipuleucel-T)

Split by applications, this report focuses on sales, market share and growth rate of Urological Cancer Drugs in each application, can be divided into

• Prostate Cancer
• Bladder Cancer
• Kidney Cancer
• Testicular Cancer

Contents

United States Urological Cancer Drugs Market Report 2017

1 UROLOGICAL CANCER DRUGS OVERVIEW

1.1 Product Overview and Scope of Urological Cancer Drugs
1.2 Classification of Urological Cancer Drugs
  1.2.1 Xofigo (Radium Ra 223 Dichloride)
  1.2.2 Jevtana (Cabazitaxel)
  1.2.3 Inlyta (Axitinib)
  1.2.4 Votrient (Pazopanib Hydrochloride)
  1.2.5 Sutent (Sunitinib Malate)
  1.2.6 Zytiga (Abiraterone Acetate)
  1.2.7 Xtandi (Enzalutamide)
  1.2.8 Opdivo (Nivolumab)
  1.2.9 Provenge (Sipuleucel-T)
1.3 Application of Urological Cancer Drugs
  1.3.1 Prostate Cancer
  1.3.2 Bladder Cancer
  1.3.3 Kidney Cancer
  1.3.4 Testicular Cancer
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Urological Cancer Drugs (2012-2022)
  1.4.1 United States Urological Cancer Drugs Sales and Growth Rate (2012-2022)
  1.4.2 United States Urological Cancer Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES UROLOGICAL CANCER DRUGS COMPETITION BY MANUFACTURERS

2.1 United States Urological Cancer Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Urological Cancer Drugs Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Urological Cancer Drugs Average Price by Manufactures (2015 and 2016)
2.4 Urological Cancer Drugs Market Competitive Situation and Trends
  2.4.1 Urological Cancer Drugs Market Concentration Rate
  2.4.2 Urological Cancer Drugs Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES UROLOGICAL CANCER DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY STATES (2012-2017)

3.1 United States Urological Cancer Drugs Sales and Market Share by States (2012-2017)
3.2 United States Urological Cancer Drugs Revenue and Market Share by States (2012-2017)
3.3 United States Urological Cancer Drugs Price by States (2012-2017)

4 UNITED STATES UROLOGICAL CANCER DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2012-2017)

4.1 United States Urological Cancer Drugs Sales and Market Share by Type (2012-2017)
4.2 United States Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Urological Cancer Drugs Price by Type (2012-2017)
4.4 United States Urological Cancer Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES UROLOGICAL CANCER DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Urological Cancer Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Urological Cancer Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES UROLOGICAL CANCER DRUGS MANUFACTURERS PROFILES/ANALYSIS

6.1 Novartis
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Urological Cancer Drugs Product Type, Application and Specification
    6.1.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.1.2.2 Jevtana (Cabazitaxel)
  6.1.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Pfizer
  6.2.2 Urological Cancer Drugs Product Type, Application and Specification
    6.2.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.2.2.2 Jevtana (Cabazitaxel)
  6.2.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Johnson & Johnson
  6.3.2 Urological Cancer Drugs Product Type, Application and Specification
    6.3.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.3.2.2 Jevtana (Cabazitaxel)
  6.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 AstraZeneca
  6.4.2 Urological Cancer Drugs Product Type, Application and Specification
    6.4.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.4.2.2 Jevtana (Cabazitaxel)
  6.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Astellas
  6.5.2 Urological Cancer Drugs Product Type, Application and Specification
    6.5.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.5.2.2 Jevtana (Cabazitaxel)
  6.5.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Bristol-Myers Squibb
  6.6.2 Urological Cancer Drugs Product Type, Application and Specification
    6.6.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.6.2.2 Jevtana (Cabazitaxel)
  6.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Abbott Laboratories
  6.7.2 Urological Cancer Drugs Product Type, Application and Specification
    6.7.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.7.2.2 Jevtana (Cabazitaxel)
  6.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Celgene Corporation
  6.8.2 Urological Cancer Drugs Product Type, Application and Specification
    6.8.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.8.2.2 Jevtana (Cabazitaxel)
  6.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Dendreon Corporation
  6.9.2 Urological Cancer Drugs Product Type, Application and Specification
    6.9.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.9.2.2 Jevtana (Cabazitaxel)
  6.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Ferring Pharmaceuticals
  6.10.2 Urological Cancer Drugs Product Type, Application and Specification
    6.10.2.1 Xofigo (Radium Ra 223 Dichloride)
    6.10.2.2 Jevtana (Cabazitaxel)
  6.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 GlaxoSmithKline
6.12 Indevus Pharmaceuticals Inc
6.13 Ipsen
6.14 Roche Healthcare
6.15 Sanofi S.A.
6.16 Tolmar Inc

7 UROLOGICAL CANCER DRUGS MANUFACTURING COST ANALYSIS

7.1 Urological Cancer Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Urological Cancer Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Urological Cancer Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES UROLOGICAL CANCER DRUGS MARKET FORECAST (2017-2022)

11.1 United States Urological Cancer Drugs Sales, Revenue Forecast (2017-2022)
11.2 United States Urological Cancer Drugs Sales Forecast by Type (2017-2022)
11.3 United States Urological Cancer Drugs Sales Forecast by Application (2017-2022)
11.4 Urological Cancer Drugs Price Forecast (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

Methodology
Analyst Introduction
Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Urological Cancer Drugs
Table Classification of Urological Cancer Drugs
Figure United States Sales Market Share of Urological Cancer Drugs by Type in 2015
Figure Xofigo (Radium Ra 223 Dichloride) Picture
Figure Jevtana (Cabazitaxel) Picture
Figure Inlyta (Axitinib) Picture
Figure Votrient (Pazopanib Hydrochloride) Picture
Figure Sutent (Sunitinib Malate) Picture
Figure Zytiga (Abiraterone Acetate) Picture
Figure Xtandi (Enzalutamide) Picture
Figure Opdivo (Nivolumab) Picture
Figure Provenge (Sipuleucel-T) Picture
Table Application of Urological Cancer Drugs
Figure United States Sales Market Share of Urological Cancer Drugs by Application in 2015
Figure Prostate Cancer Examples
Figure Bladder Cancer Examples
Figure Kidney Cancer Examples
Figure Testicular Cancer Examples
Figure United States Urological Cancer Drugs Sales and Growth Rate (2012-2022)
Figure United States Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Table United States Urological Cancer Drugs Sales of Key Manufacturers (2015 and 2016)
Table United States Urological Cancer Drugs Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Urological Cancer Drugs Sales Share by Manufacturers
Figure 2016 Urological Cancer Drugs Sales Share by Manufacturers
Table United States Urological Cancer Drugs Revenue by Manufacturers (2015 and 2016)
Table United States Urological Cancer Drugs Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Urological Cancer Drugs Revenue Share by Manufacturers
Table 2016 United States Urological Cancer Drugs Revenue Share by Manufacturers
Table United States Market Urological Cancer Drugs Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Urological Cancer Drugs Average Price of Key Manufacturers in 2015
Figure Urological Cancer Drugs Market Share of Top 3 Manufacturers
Figure Urological Cancer Drugs Market Share of Top 5 Manufacturers
Table United States Urological Cancer Drugs Sales by States (2012-2017)
Table United States Urological Cancer Drugs Sales Share by States (2012-2017)
Figure United States Urological Cancer Drugs Sales Market Share by States in 2015
Table United States Urological Cancer Drugs Revenue and Market Share by States (2012-2017)
Table United States Urological Cancer Drugs Revenue Share by States (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by States (2012-2017)
Table United States Urological Cancer Drugs Price by States (2012-2017)
Table United States Urological Cancer Drugs Sales by Type (2012-2017)
Table United States Urological Cancer Drugs Sales Share by Type (2012-2017)
Figure United States Urological Cancer Drugs Sales Market Share by Type in 2015
Table United States Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
Table United States Urological Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Type (2012-2017)
Table United States Urological Cancer Drugs Price by Type (2012-2017)
Figure United States Urological Cancer Drugs Sales Growth Rate by Type (2012-2017)
Table United States Urological Cancer Drugs Sales by Application (2012-2017)
Table United States Urological Cancer Drugs Sales Market Share by Application (2012-2017)
Figure United States Urological Cancer Drugs Sales Market Share by Application in 2015
Table United States Urological Cancer Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Urological Cancer Drugs Sales Growth Rate by Application (2012-2017)
Table Novartis Basic Information List
Table Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Novartis Urological Cancer Drugs Sales Market Share (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Pfizer Urological Cancer Drugs Sales Market Share (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Johnson & Johnson Urological Cancer Drugs Sales Market Share (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table AstraZeneca Urological Cancer Drugs Sales Market Share (2012-2017)
Table Astellas Basic Information List
Table Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Astellas Urological Cancer Drugs Sales Market Share (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Bristol-Myers Squibb Urological Cancer Drugs Sales Market Share (2012-2017)
Table Abbott Laboratories Basic Information List
Table Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Abbott Laboratories Urological Cancer Drugs Sales Market Share (2012-2017)
Table Celgene Corporation Basic Information List
Table Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Celgene Corporation Urological Cancer Drugs Sales Market Share (2012-2017)
Table Dendreon Corporation Basic Information List
Table Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Dendreon Corporation Urological Cancer Drugs Sales Market Share (2012-2017)
Table Ferring Pharmaceuticals Basic Information List
Table Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Ferring Pharmaceuticals Urological Cancer Drugs Sales Market Share (2012-2017)
Table GlaxoSmithKline Basic Information List
Table Indevus Pharmaceuticals Inc Basic Information List
Table Ipsen Basic Information List
Table Roche Healthcare Basic Information List
Table Sanofi S.A. Basic Information List
Table Tolmar Inc Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Urological Cancer Drugs
Figure Manufacturing Process Analysis of Urological Cancer Drugs
Figure Urological Cancer Drugs Industrial Chain Analysis
Table Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
Table Major Buyers of Urological Cancer Drugs
Table Distributors/Traders List
Figure United States Urological Cancer Drugs Production and Growth Rate Forecast (2017-2022)
Figure United States Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Table United States Urological Cancer Drugs Production Forecast by Type (2017-2022)
Table United States Urological Cancer Drugs Consumption Forecast by Application (2017-2022)
Table United States Urological Cancer Drugs Sales Forecast by States (2017-2022)
Table United States Urological Cancer Drugs Sales Share Forecast by States (2017-2022)